Call for a Free Phone Consultation


chicago drug defect lawyerFor years, Zantac was considered to be an effective treatment for heartburn, acid reflux, ulcers, and other gastrointestinal issues. However, Zantac and ranitidine, the generic equivalent of the drug, were taken off the market in 2020. This was done in response to studies that discovered that the drug could break down and form a substance that has been linked to multiple types of cancer. Because of the wide use of Zantac, millions of people may have been exposed to this substance, potentially causing them to experience serious illnesses. Numerous lawsuits have been filed against the manufacturers of Zantac and ranitidine, and in the coming months, these cases will begin being heard in courts.

What Is the Current Status of Zantac Litigation?

People who have suffered injuries or damages that were related to their use of Zantac may be able to pursue product liability lawsuits against the drug’s manufacturers. As of 2022, multiple state-level lawsuits have been filed, and over 2,000 federal cases are also being pursued. The federal lawsuits have been combined into multi-district litigation (MDL). A class action lawsuit is scheduled to begin in August 2022, and bellwether trials in the MDL cases are expected to commence in October 2022 and early 2023.

Lawsuits are being pursued against multiple companies that have manufactured and sold Zantac. GSK, formerly known as GlaxoSmithKline, originally launched Zantac in the 1980s, and Sanofi owned the rights to the over-the-counter version of the drug. Other companies have also released products containing ranitidine, including Pfizer, Johnson & Johnson, Haleon, and Boehringer Ingelheim. Through lawsuits, users of the drugs may be able to show that these companies knowingly allowed a dangerous drug to be sold to consumers.

Back to Top